Screener
Spyre Therapeutics, Inc. SYRE Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
FAQ
- What is Spyre Therapeutics, Inc.'s current ratio?
- Spyre Therapeutics, Inc. (SYRE) reported current ratio of 9× in Q1 2026.
- How has Spyre Therapeutics, Inc.'s current ratio changed year-over-year?
- Spyre Therapeutics, Inc.'s current ratio increased by 11.3% year-over-year, from 8.1× to 9×.
- What is the long-term trend for Spyre Therapeutics, Inc.'s current ratio?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s current ratio has grown at a 7.8% compound annual growth rate (CAGR), from 9.1× to 13.3×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.
Ask your AI about Spyre Therapeutics, Inc.'s current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude